Inc. (NASDAQ:INCR) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 — Submission of Matters to a Vote of Security Holders
The 2018 Annual Meeting of Stockholders (the “Annual Meeting”) of Milestone Scientific Inc. (the “Company”) was held on May 30, 2018. At the Annual Meeting, the Company’s stockholders:
|
Elected six incumbent directors to serve until the next annual meeting of the Company’s stockholders or until their respective successors have been duly elected and qualified; and |
|
Approved, on an advisory basis, the appointment of Friedman LLP as the Company’s independent auditors for the fiscal year ending December 31, 2018. |
The number of votes cast for, against or withheld and the number of abstentions and broker non-votes with respect to each Proposal is set forth below.
|
Proposal 1 |
Shares For |
Shares Withheld |
Broker Non-Votes |
|
Leslie Bernhard |
11,720,914 |
164,412 |
16,052,871 |
|
Leonard Osser |
11,723,966 |
161,360 |
16.052,871 |
|
Leonard M. Schiller |
11,723,966 |
161,360 |
16,052,871 |
|
Gian Domenico Trombetta |
11,723,971 |
161,355 |
16,052,871 |
|
Edward Zelnick, M.D. |
11,720,994 |
164,332 |
16,052,871 |
|
Michael McGeehan |
11,721,655 |
163,671 |
16,052,871 |
|
Proposal 2 |
Shares For |
Shares Against |
Shares Abstaining |
Broker Non-Votes |
|
Advisory approval of Friedman LLP as the Company’s independent auditors for the 2018 fiscal year |
27,722,667 |
215,530 |
-0- |
-0- |
About Inc. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
